Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial

More on Type 2 diabetes

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• GLP-1 agonists linked to lower dementia risk after COVID-19

  Drug Design, Development and Therapy · 5 Oct 2026

  

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• Orforglipron matches insulin glargine on cardiovascular safety

  Lancet · 4 Oct 2026